252 related articles for article (PubMed ID: 21327970)
1. Genotoxicity and carcinogenicity studies of antihistamines.
Brambilla G; Mattioli F; Robbiano L; Martelli A
Arch Toxicol; 2011 Oct; 85(10):1173-87. PubMed ID: 21327970
[TBL] [Abstract][Full Text] [Related]
2. Genotoxic and carcinogenic effects of gastrointestinal drugs.
Brambilla G; Mattioli F; Martelli A
Mutagenesis; 2010 Jul; 25(4):315-26. PubMed ID: 20478972
[TBL] [Abstract][Full Text] [Related]
3. Genotoxic and carcinogenic effects of antipsychotics and antidepressants.
Brambilla G; Mattioli F; Martelli A
Toxicology; 2009 Jul; 261(3):77-88. PubMed ID: 19410629
[TBL] [Abstract][Full Text] [Related]
4. Genotoxicity and carcinogenicity studies of antihypertensive agents.
Brambilla G; Martelli A
Mutat Res; 2006 Mar; 612(2):115-49. PubMed ID: 16458045
[TBL] [Abstract][Full Text] [Related]
5. Genotoxicity and carcinogenicity studies of bronchodilators and antiasthma drugs.
Brambilla G; Mattioli F; Robbiano L; Martelli A
Basic Clin Pharmacol Toxicol; 2013 May; 112(5):302-13. PubMed ID: 23374861
[TBL] [Abstract][Full Text] [Related]
6. Studies on genotoxicity and carcinogenicity of antibacterial, antiviral, antimalarial and antifungal drugs.
Brambilla G; Mattioli F; Robbiano L; Martelli A
Mutagenesis; 2012 Jul; 27(4):387-413. PubMed ID: 22228823
[TBL] [Abstract][Full Text] [Related]
7. Genotoxicity and carcinogenicity studies of analgesics, anti-inflammatory drugs and antipyretics.
Brambilla G; Martelli A
Pharmacol Res; 2009 Jul; 60(1):1-17. PubMed ID: 19427580
[TBL] [Abstract][Full Text] [Related]
8. Genotoxicity and carcinogenicity testing of pharmaceuticals: correlations between induction of DNA lesions and carcinogenic activity.
Brambilla G; Mattioli F; Robbiano L; Martelli A
Mutat Res; 2010; 705(1):20-39. PubMed ID: 20206292
[TBL] [Abstract][Full Text] [Related]
9. Genotoxicity and carcinogenicity studies of benzodiazepines.
Brambilla G; Carrozzino R; Martelli A
Pharmacol Res; 2007 Dec; 56(6):443-58. PubMed ID: 17920927
[TBL] [Abstract][Full Text] [Related]
10. Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals.
Brambilla G; Martelli A
Mutat Res; 2009; 681(2-3):209-229. PubMed ID: 18845271
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity.
Kirkland D; Aardema M; Henderson L; Müller L
Mutat Res; 2005 Jul; 584(1-2):1-256. PubMed ID: 15979392
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumour profiles.
Kirkland D; Aardema M; Müller L; Makoto H
Mutat Res; 2006 Sep; 608(1):29-42. PubMed ID: 16769241
[TBL] [Abstract][Full Text] [Related]
13. Update of carcinogenicity studies in animals and humans of 535 marketed pharmaceuticals.
Brambilla G; Mattioli F; Robbiano L; Martelli A
Mutat Res; 2012; 750(1):1-51. PubMed ID: 21968027
[TBL] [Abstract][Full Text] [Related]
14. The results of assays in Drosophila as indicators of exposure to carcinogens.
Vogel EW; Graf U; Frei HJ; Nivard MM
IARC Sci Publ; 1999; (146):427-70. PubMed ID: 10353398
[TBL] [Abstract][Full Text] [Related]
15. An update on the genotoxicity and carcinogenicity of marketed pharmaceuticals with reference to in silico predictivity.
Snyder RD
Environ Mol Mutagen; 2009 Jul; 50(6):435-50. PubMed ID: 19334052
[TBL] [Abstract][Full Text] [Related]
16. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines.
Sistare FD; Morton D; Alden C; Christensen J; Keller D; Jonghe SD; Storer RD; Reddy MV; Kraynak A; Trela B; Bienvenu JG; Bjurström S; Bosmans V; Brewster D; Colman K; Dominick M; Evans J; Hailey JR; Kinter L; Liu M; Mahrt C; Marien D; Myer J; Perry R; Potenta D; Roth A; Sherratt P; Singer T; Slim R; Soper K; Fransson-Steen R; Stoltz J; Turner O; Turnquist S; van Heerden M; Woicke J; DeGeorge JJ
Toxicol Pathol; 2011 Jun; 39(4):716-44. PubMed ID: 21666103
[TBL] [Abstract][Full Text] [Related]
17. Review of alternative methods of carcinogenicity testing and evaluation of human pharmaceuticals.
Van Deun K; Van Cauteren H; Vandenberghe J; Canning M; Vanparys P; Coussement W
Adverse Drug React Toxicol Rev; 1997 Nov; 16(4):215-33. PubMed ID: 9608857
[TBL] [Abstract][Full Text] [Related]
18. A review of the genotoxicity of marketed pharmaceuticals.
Snyder RD; Green JW
Mutat Res; 2001 May; 488(2):151-69. PubMed ID: 11344042
[TBL] [Abstract][Full Text] [Related]
19. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Gaylor DW
Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
[TBL] [Abstract][Full Text] [Related]
20. The mouse carcinogenicity study is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides.
Billington R; Lewis RW; Mehta JM; Dewhurst I
Crit Rev Toxicol; 2010 Jan; 40(1):35-49. PubMed ID: 20144135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
